Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
antagomir-1204
- Development stage
- Preclinical
- Lead developer
- Lawrence Berkeley National Laboratory
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous, Intraperitoneal, Intratumoral
01
Overview
antagomir-1204 (also known as hsa-miR-1204 antagomir) is a chemically-modified antisense oligonucleotide designed to specifically hybridize with and inhibit mature microRNA-1204 (miR-1204). It features phosphorothioate modifications, 2'-O-methyl (2'-methoxy) modifications, and a 3' cholesterol conjugate to enhance stability, cellular uptake, and in vivo activity. In preclinical research, antagomir-1204 has been investigated for its ability to inhibit cell proliferation and induce apoptosis in PVT1-amplified ovarian and breast cancer cell lines, where miR-1204 is typically overexpressed and acts as an oncogene.
- Other names
- antagomir-1204antagomir1204antagomir 1204hsa-miR-1204 antagomirhsa-miR1204 antagomirhsa-miR 1204 antagomirmiR-1204 antagomirmiR1204 antagomirmiR 1204 antagomir
02
Targets
miR-1204 (microRNA-1204)
Beyond the preview
Go deeper on antagomir-1204.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on antagomir-1204.